<SEC-DOCUMENT>0001167379-25-000023.txt : 20250528
<SEC-HEADER>0001167379-25-000023.hdr.sgml : 20250528
<ACCEPTANCE-DATETIME>20250528171023
ACCESSION NUMBER:		0001167379-25-000023
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20250528
FILED AS OF DATE:		20250528
DATE AS OF CHANGE:		20250528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALCON INC
		CENTRAL INDEX KEY:			0001167379
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				980205094
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31269
		FILM NUMBER:		25996407

	BUSINESS ADDRESS:	
		STREET 1:		6201 SOUTH FREEWAY
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76134
		BUSINESS PHONE:		817 293 0450

	MAIL ADDRESS:	
		STREET 1:		CHEMIN DE BLANDONNET 8
		STREET 2:		1214 VERNIER
		CITY:			GENEVA
		STATE:			V8
		ZIP:			0000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kxarx1551230may2025.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i237aa382f0d7424c846ddc38cc3519a4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_________________</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM 6-K </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_________________</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:13pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:13pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:700;line-height:120%">May 28, 2025</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commission File Number&#58; 001-31269 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_________________</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:22pt;font-weight:700;line-height:120%">ALCON INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant Name)</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rue Louis-d'Affry 6 </font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1701, Fribourg, Switzerland </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive office)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20&#8209;F or Form 40-F&#58;  Form 20-F </font><font style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Form 40-F </font><font style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i237aa382f0d7424c846ddc38cc3519a4_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:130%">EXHIBIT INDEX</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br>Number</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="tryptyrapprovalpressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press release issued by Alcon Inc. dated </a><a href="tryptyrapprovalpressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">M</a><a href="tryptyrapprovalpressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ay</a><a href="tryptyrapprovalpressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="tryptyrapprovalpressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a><a href="tryptyrapprovalpressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2025</a></font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i237aa382f0d7424c846ddc38cc3519a4_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALCON INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David J. Endicott</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; David J. Endicott</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Representative</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Timothy C. Stonesifer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Timothy C. Stonesifer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Representative</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:288pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tryptyrapprovalpressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i55ca0e463560482d85d2f1c195a92b29_1"></div><div style="min-height:0pt;width:100%"><div><font><br></font></div></div><div><img alt="logopressrelease2a01a.jpg" src="logopressrelease2a01a.jpg" style="height:294px;margin-bottom:5pt;vertical-align:text-bottom;width:816px"></div><div id="i55ca0e463560482d85d2f1c195a92b29_4"></div><div><font style="color:#003595;font-family:'Open Sans',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.49pt">In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 1</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">1-2</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">4</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ad hoc announcement pursuant to Art. 53 LR</font></div><div style="text-indent:-13.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#00b0f0;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">GENEVA, </font><font style="color:#00b0f0;font-family:'Open Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">May 28</font><font style="color:#00b0f0;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">, 2025</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%"> </font><font style="color:#00b0f0;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> Alcon (SIX&#47;NYSE&#58; ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">  </font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">5-7</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%"> Many commonly used DED treatment options have limitations, including slow onset, patient dissatisfaction and poor adherence.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">8-14</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%"> Among surveyed dry eye patients, only 13% felt their dry eye was well managed.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">14*</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8220;Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care company,&#8221; said David Endicott, CEO of Alcon. &#8220;We look forward to making this new treatment available to millions of patients affected by Dry Eye Disease. We believe TRYPTYR is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients (randomized 1&#58;1 to TRYPTYR or vehicle) with a history of DED.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">1-2</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p&#60;0.0001).</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">1-2-</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Consistent results were observed at all timepoints through Day 90. TRYPTYR demonstrated statistically significant natural tear production as early as Day 1.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">1-2</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">1</font></div></div></div><div id="i55ca0e463560482d85d2f1c195a92b29_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8220;Many of my patients continue to face frustrating challenges with dry eye management, and there is a clear need for additional treatment options,&#8221; said Marjan Farid, MD, Professor of Ophthalmology at the University of California, Irvine. &#8220;TRYPTYR is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of Dry Eye Disease.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Studies in animals suggest that acoltremon, the active substance in TRYPTYR, is an agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors. TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action for TRYPTYR in DED is unknown.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">TRYPTYR is available in easy-to-use, single dose vials&#58; one drop per eye, two times a day.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">3 </font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing TRYPTYR to other markets in the future.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">INDICATIONS AND USAGE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Warnings and Precautions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Potential for Eye Injury and Contamination&#58; </font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:115%">Use with Contact Lenses&#58; </font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Adverse Reactions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">In clinical trials, the most common adverse reaction was instillation site pain (50%).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Please visit https&#58;&#47;&#47;tryptyr.myalcon.com&#47;pi&#47; for the TRYPTYR Full Prescribing Information.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">2</font></div></div></div><div id="i55ca0e463560482d85d2f1c195a92b29_19"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#003595;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as&#58; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;commitment,&#8221; &#8220;look forward,&#8221; &#8220;maintain,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar references to future periods.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#003595;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">About Dry Eye</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Dry Eye Disease (DED) is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the U.S. and an estimated 719 million more adults globally.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">15</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> Many existing prescription options for DED are generally regarded by many Eye Care Professionals and patients as inadequate due to low treatment efficacy, slow onset of action and&#47;or poor tolerability.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">16</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#003595;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">About Alcon</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people&#8217;s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#003595;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">References</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%">*Based on an online survey conducted by Chronic Dry Eye from February to April 2021 among 415 responders who reported being diagnosed with chronic dry eye. 44% reported a severe level of chronic dry eye (i.e., levels 3 and 4).</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Data on File for COMET-2 Phase 3 Study. Alcon 2025.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Data on File for COMET-3 Phase 3 Study. Alcon 2025.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">TRYPTYR</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> U.S. FDA Prescribing Information. 2025.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">2023 Dry Eye Products Markets Report, Market Scope, 2023. </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017&#59;15(3)&#58;276-283. doi&#58; 10.1016&#47;j.jtos.2017.05.008.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Nattinen J, Aapola U, Nukareddy P, Uusitalo H. Looking deeper into ocular surface health&#58; an introduction to clinical tear proteomics analysis. Acta Ophthalmol. 2022&#59;100&#58;486-498. doi&#58; 10.1111&#47;aos.15059.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017&#59;15&#58;438-510. doi&#58; 10.1016&#47;j.jtos.2017.05.011.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007&#59;114(1)&#58;76-79. doi&#58; 10.1016&#47;j.ophtha.2006.05.077.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:9.21pt">Semba CP, Gadek TR. Development of lifitegrast&#58; a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016&#59;10&#58;1083-1094. doi&#58; 10.2147&#47;OPTH.S110557.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">Restasis. Prescribing Information. Allergan&#59; 2012. Accessed July 8, 2024. </font><font style="color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">http&#58;&#47;&#47;www.accessdata.fda.gov&#47;drugsatfda_docs&#47;label&#47;2012&#47;050790s020lbl</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.pdf</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">) in the US and Canada&#58; retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021&#59;15&#58;1041-1054. doi&#58; 10.2147&#47;OPTH.S296510.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019&#59;8(3)&#58;407-420. doi&#58; 10.1007&#47;s40123-019-0188.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, Harrison DJ. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at&#58; American Society for Cataract and Refractive Surgery Conference&#59; April 5-6, 2024&#59; Boston, MA.  </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">Morse H, Henneberger S, Reed J, et al. 2021 in American survey findings&#58; living with chronic dry eye. ChronicDryEye. August 10, 2021. Accessed September 23, 2024. </font><font style="color:#0000ff;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;chronicdryeye.net&#47;infographic&#47;in-america-findings</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">The Relationship Between Dry Eye Disease and Digital Screen Use - PMC (nih.gov).</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:3.21pt">Improved Dry Eye Drugs for 2022 and Beyond&#59; https&#58;&#47;&#47;www.aao.org&#47;eye-health&#47;tips-prevention&#47;new-dry-eye-treatments-ocular-surface-disease.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">4</font></div></div></div><div id="i55ca0e463560482d85d2f1c195a92b29_46"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:7pt;padding-right:13.5pt"><font style="color:#003493;font-family:'Open Sans',sans-serif;font-size:9pt;font-weight:700;line-height:144%">Connect with us on </font><img alt="alcon2q19pressrelease_imagb.gif" src="alcon2q19pressrelease_imagb.gif" style="height:37px;margin-bottom:5pt;vertical-align:text-bottom;width:37px"><font style="color:#003493;font-family:'Open Sans',sans-serif;font-size:9pt;font-weight:700;line-height:144%">    </font><img alt="alcon2q19pressrelease_imagc.gif" src="alcon2q19pressrelease_imagc.gif" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:41px"></div><div style="margin-top:3pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font><br></font></div><div id="i55ca0e463560482d85d2f1c195a92b29_49"></div><div style="padding-right:13.5pt"><font style="color:#00aeef;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:144%;text-decoration:underline">Investor Relations</font></div><div style="padding-right:13.5pt"><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">Daniel Cravens</font></div><div style="padding-right:13.5pt"><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">Allen Trang</font></div><div style="padding-right:13.5pt"><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">+ 41 589 112 110 (Geneva)</font></div><div style="padding-right:13.5pt"><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">+ 1 817 615 2789 (Fort Worth)</font></div><div style="padding-right:13.5pt"><font style="color:#0094ff;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%;text-decoration:underline">investor.relations&#64;alcon.com</font></div><div style="padding-right:13.5pt"><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00aeef;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:700;line-height:144%;text-decoration:underline">Media Relations</font></div><div style="padding-right:13.5pt"><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">Steven Smith</font></div><div><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">+ 41 589 112 111 (Geneva)</font></div><div style="padding-right:13.5pt"><font style="color:#221f1f;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%">+ 1 817 615 2666 (Fort Worth)</font></div><div style="padding-right:13.5pt"><font style="color:#0094ff;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:144%;text-decoration:underline">globalmedia.relations&#64;alcon.com</font></div><div><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:9pt;font-weight:400;line-height:144%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Open Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>alcon2q19pressrelease_imagb.gif
<TEXT>
begin 644 alcon2q19pressrelease_imagb.gif
M1TE&.#EA2 !( /(      $)GLDYQMUIZO'&-Q7V7RO___P   "'Y! $
M+     !( $@ 0@C_  $(#$"PH,&#"!,J7,BPH4  #2-*G$BQHL6)  QHW,BQ
M8\>+("-F],@QI$F0(TD:@'BRY4&5,&-N9.G294J2-&OJ1'C38\Z=0 /T[/@S
MJ-&C2!T.A9FTX@"9,IM27#I3:D6H6#T2L&J0@->O7ZEJ! "VK "N$L6N1'M2
M;5&V4V.^G0K7Z-RZ>(^6]7HV;T,!:E7ZY9F5Y&"#@0'T/<S0+>.T<A\7+$SY
M[E'*A>MBQFH9KF/)C2.#7OAY=,+2I@^B3EUPM<7..EU/A<T:<>W;N'/KEDQ
MH$S:< %C-AU8L&3AFPV +L[T<0&H O=ZE1RX@&[9J;$3%YU;.]Z'X!_*0@U/
M'FYRJ-;9GI>YF.MZF,!WOE<97^=\DENI<\?M??G^V_WI!]]N 3Y6(&,''I;@
58 OZU6!>#]IF580$@2=5A \%!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>alcon2q19pressrelease_imagc.gif
<TEXT>
begin 644 alcon2q19pressrelease_imagc.gif
M1TE&.#EABP"  /0       !WM1" NB"(OC"1PT"9R%"BS&"JT7"SUH"[VI#$
MWZ#,X[#5Z,#=[=#F\>#N]O#W^____P
M                         "'Y! $     +     "+ (  1 C_  $('"@P
M@,&#"!,J7,BPH<.'$"-*7$BPHD6"$S-JW,BQHT>#%S%^'$FRI$F*(0MF+!"A
MI<N7,&,2.$FS)L*4*B<:B,FSIP&;0$_B!!"TJ-&:0SGV7-H2(M.># LT>+KT
MP4^A.)52C>ETZ\L'7L/V1. QZ4:Q+KNBA=E@0$,!"]:Z3,#1K$:Y:L4VX,AR
M;=VL9_T^Q-N1L$:[&0TW5'Q7\&' C='F#>N1L43$$RTKU"R1\T/,1T.+G@AZ
MM.G3"8?F1,UZM&JBK6.?+ATQKM<%LG/37BPW;6[4NQ_:WHK[=^O@QI.7A9S8
M,6^Q!X?W[@G![4?D##T?G,[=JX..V!=J_S<X?69&".,9AM_L//O: H7;7V:>
M63Y[R?'Q/TZI5?]SZ/D!N%](_0GX'V4!(CC@104J>*!7E=D'T7K*51C1:Q9F
MN-%K%6GHX6<<PO;AB"#21^*)"E&(8H8J*E2  TLU8-Z*-K480%]HS4@C22W"
MV-MW._)HXD-@]?9 D$+RI]%.:UV%Y'5#ZE0D3P_ ]Z1)-EYY7)1:)E1  @PT
M,*4##320P $Z(L6E0^FU=P!ZW;4$09K@K?G@5I/AJ4"<3]&UG)*1&>@>GX2^
M1.=\@#;GWZ"%-FKE@A8U".%@TRDPD8]H[;6AG8PZV&E83DZ40'HH)5K?HN*M
M1=9& Y":(J>IHO]ZGUB/!NHIH@0&)FM"KL8J**X,ZOKKK+>>.NR$L!([*9L2
M1M3K3<GRVNQVTU*Z:XFYVKKLG51%>*U#6;99+;/?-A3NN,]*6ZYZT7896Y;N
MF@9OO**I1J^&(:YV+W#YBK0O:_V*^*]L(0ZLG+T&']QNPD;-RS!-#C^,Y<(2
MUTBQBPN,N4"M%9M[L4&C4N5GQZ5FFU'(8:U*,K2F1C356IJN#-+">_9FJ<P!
MM-@=SCDOO#/.+4J'5G$RVSBE6$?RG*705!$-],<!,,W3S3S/W/)&!F3LD@,+
MA%JUU29_W3#48F<4<=D7DOUA 0O 214$&UM\=9YX6GOK "]SUX  $\__;7>Q
MZCHH-7=S)AEV9^CB-SB?0/YYN+.)B\5DHS%!P'>=?I-[+$*4%YKT7YES^Q3=
MG=N,^>.DC_YWZ=R='JRV=6O.'0,(U%J  F[+I;+9%XL[W<@.+?Y4S+R'_FGL
MHE-%/$23(PTZZJLC?_Q6#&S$0+I@OZ[HYM2.NQ".W'MLO*^ <[X6U2MAW_/X
MRDI/OE<<&UL^N+U'3FN"VY)6_[KJD^?]J^P+W/S\MZ[D+>5YVI-?_M[G/@4V
M$%D!-!___L? ;FTJ@MT+7P#ZMT$*L@QZLEM@^RPHJ0=B*X&(FV !IZ<Z2'5(
M6 /LX HKV,+B@=" 4(D>"6$H0@C>D(5,25T08?%G0OIAD( :Y*#ZSJ5"#>*0
M)PB,% ^+B,08/I$K%_PA#8<80BIV<8?Z.Z(,D^A! ?;PA%)$6U'.ID8C:K&-
EKDLC'-4DQCGZ$(5V--P;\Y@VA/$12@7[8Q8#)C!! C!? 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logopressrelease2a01a.jpg
<TEXT>
begin 644 logopressrelease2a01a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1V<17AI9@  34T *@    @ "  +  (
M   F   (>@$2  ,    !  $   $Q  (    F   (H $R  (    4   (Q@$[
M  (    1   (VH=I  0    !   ([)R=  $    B   1<.H<  <   @,
M;@  $9(<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %=I;F1O
M=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0 5VEN9&]W<R!0:&]T
M;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-  R,#$Y.C X.C$W(#$R.C$Q.C0Q
M $-H96YG+"!#:')I<W1I;F$    &D ,  @   !0  !%&D 0  @   !0  !%:
MDI$  @    ,R,P  DI(  @    ,R,P  H $  P    $  0  ZAP !P  " P
M  DZ     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        ,C Q
M.3HP.#HQ-R Q,3HU-CHP-P R,#$Y.C X.C$W(#$Q.C4V.C W    0P!H &4
M;@!G "P ( !# &@ <@!I ', = !I &X 80     & 0,  P    $ !@   1H
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MC0 HHHHT ****- "BBBC0 HHHHT ****- "BBBC0 HHHHT ****- "BBBC0
MHHHHT ****- "BBBC0 HHHHT ****- "BBBC0 HHHHT ****- "BBBC0 HHH
MHT ****- "BBBC0 HHHHT ****- "BBBC0 HHHHT ****- "BBBC0 HHHHT
M****- "BBBC0 HHHHT ****- "BBBC0 HHHHT ****- "BBBC0 HHHHT ***
M*- "BBBC0 HHHHT ****- "BBBC0 HHHHT ****- "BBBC0 HHHHT ****0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%=?H_P '/'_B#38-0TOP/XCU/3[A=T5W9:1<2Q.H;&X2*I4Y]C6-
M2M3HV]I*URHQE*]D<A16QXF\&^(/!=U';^(-"U30IYH_,BCU*SD@++D@MAU!
MP"/TK'K2,XSBI1=TQ--;A16MX;\):[XROFLM!T:_UN]5/,-OI]J\[A0<%L)G
MY<D<^];>J?!CX@Z%I]Q?ZEX%\2:?I]NGF375UI$\44:CJ6D90NWWS6<J]*$E
M&4DF_P!2E"4E=(XZBBBM^MB HHHI M0HHHIZ %%%%( HHHHT **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>GFKYLSBU_=.;"Q<<-*YY;_P3D\&6>A_L_Q:S'&OVS6[Z>:64_>VQNT,:^P
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M@X;UPLO\1Q9C?V@4445]:>4%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3CTS25K@\%2P5-PI=7<BK5E6=Y!1117<8A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/\C./UH'/M2"XE%%%,84444@>FX4444!N%%%% !1110 4444 %%%% !1110
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MQZ[I57^0J_;_  <\)VZX:PDE;UDNG_H:[?</4T<CJ"/R']:OEBMSD>:8R?\
MR\9S$/PS\*0-E=$MR?\ :W-_,U?B\%Z!"NU-%L0/>W4_TK9P<_=Q_GZ4X1O_
M '&/X'^F:7N+<QEBL7/_ )>2,^/1=.A^YI]HGT@3_"K:1I']Q%3_ '5 J:.U
MFF_U<;,/]D$_TK0@\+:Q<?ZG2KR;_KG S?T%2ZE-;M$>SQ53I+\3,5BOW3M^
MG%)]./IQ720_#?Q5<?ZOPWJI_P"W&4?S6KL/P?\ &=QT\.7Z_P"]"5_G7,\;
MAEO47WFWU/'2VIR_$X[)]3^='U.?KS7H$?P!\?R?=\.3?C)&/YM5V/\ 9O\
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M^M>T:;^RCXSO/FG;3[1?[KW#,W_CJ$5U>F?L=2R8>\\2QA?[EO:D_P#CQ?\
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M/3I\,Y53VHH\?M?V7_ =O_K;">?_ *Z7;C_T$BMNT^ /@.S^YX>A;_KH[O\
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M[3B<'??!7PM>?-'#<6C_ /3&X+?^A9KG[[]GNW;FQUB13_=FAW_^@XKUOG.
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M'\Z]>TK]GVXD"R:AJT:+_P \[1"__CYX_2NNTOX.>%]-^9[:6_D_OW4N/T7
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M2>3S]>:^LM6_9#T&Z5CINK7UDYZ+,%E4?A@']:X'6OV1_$UCN;3]0LM01?\
MGH6B8_\  2"/_'J]JCQ#@*WV[>J/F<1PKFV'^Q?T/"O?OZ]Z;<0I>1[)T6>/
M^Y*-R_D:[G6O@MXTT/=]H\/W;J/XK=1*/_'=U<?<V<]I,8IX9()5^\CJ01^!
M _G7LT\50K?PYIGS]3"XG#?%&4?O.3U+X:^&M6'[_1K=3_>@!C_]!(KE-4^
M6DW6Y[#4+JS]/,"RI^G->I<L,]O51D?SIN!Z9/K75[-=$:T<TQ>'_AS9X'JG
MP'U^SRUI<V=\GU,3?KFN2U3P3KVC,PN])NHU_OJN\?I7U3P.@Q3MQVD9./3M
M62IQ?PZGO4>)L7#^)%2/CDC;D' 8=0>/T.#0.?8^E?6>I^&-(UD'[;IMM<D]
M6>(;OSZUQVJ? _P[??/;"ZT]_6.8.GY-DUFZ;1[^'XHH5/=JKE/GRBO5-4^
M.IP$FPU"WN1_<G!B;\^E<7JWP_\ $.B[C=:3<-'_ ,](,2+_ -]+N_E6=F?0
M4<SPF(_AU$SGZ*-I&0<JPZ@C'Z'!I?Y^E2>FFI;,2BBB@+A1110/;<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH>@!12<@9)4?C@&K5EI]UJDPBL[66YE/
M1(4+'_/XT&<JD::O-V*U%=YH_P %O$NJ*))X8=-B_O7+Y/Y#FN[T?X!Z5:;)
M-2O;B^/=(P(D_P :T4&SQ<1G6#P_VK^AX2V 0,'=Z9_IR:W])\ ^(-<P;/2Y
MVC_YZ2#8O_?1_P *^C]'\'Z)H(_T'2[> _WMFYOS.36ON/')SZYJU274^8Q'
M%5OX,#Q#2?@#J$V'U+4;>T7_ )YVX,K_ )]*[/1_@OX9TKYIHIM1D];F7 _)
M<"N\].X].U*>F%)'XUK[)'SM?.L=7=I2MZ%73])L=)C"65E!: =##$JG\P,U
M9YR#GGUIRY9@-I)/3'(_//\ 2M_P_P##WQ+XHV?V7HMY=HW_ "U6(B,?\#.%
M_6HJ5J='^))(\Q0KXMVBG/[SGF^8Y8[C_M<TO.<Y/YU[9X=_9/\ %>I!7U*>
MTTI&ZJQ,KK_P%>/_ !ZO2_#_ .R7X;L2CZI>WFIR=X]XA0_@/F_\>KPL1Q!@
M:&TK^A])A.%LTQ*OR<OJ?(ZAFP N[/0*,G]#_2N@T/X?^)/$NS^S-$O;I'^[
M,L1$9_X&<+^M?=&A_"3PCX=VFQT&SBD7I*\?F2?]]MEOUKJUMTC7:B!1[5\]
M6XJ?_+FG]Y]AA>!'_P Q-;[CXPT']E;QCJ6&O?LNF!ARLLN]E_! 1_X]7I&A
M_L?:3 BMJVM7EV_=;:-85_7<:^BMHZ=12[1Z5X-?/\PK_;MZ'U6$X1RO"[PY
MO4\XT/X"^!M#P8M"@G<=7O"9R?P<D5W5CI-EI<"PVMM%;0KTCA0(H_ 5=VBC
M:*\2I7JUOXDF_F?3T<%A\/\ P8*/HB-5'0  4C9_ND_C4NT4A4&N>R.WT&A1
M@#& .U.P#2[1119 +1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 2D*CN*7 I: (L+@^_H#25+1M'I
M2U[B(E1<8P"/3%9VJ>']+UF$Q7^GVUY$>J3PAQ^1%:VT4;151;A\+L9RIPJ?
M&KGE6O\ [.?@76\R'2A8R_\ /2UE9/\ QW./TKSG7?V/;=LG2->EB Z)>1!\
M_P# EQ_Z#7TWM'^32% >HS^->G1S3&4/AJ,\/$</Y;B?CHI>FGY'Q%KG[,?C
M?1U+Q6<&I(!UM)P?T8*?TKSO6/"FL^'WVZEI=Y98ZF:!D'YG K](?+7TJ*:Q
MM[A"DL*2(>JLH(KZ"CQ1B8_Q8J7X'R>*X&PE1?[/-P_$_,_/S;>OJ!RP_6@\
M^OU[U][>(?@AX+\11G[5H5LC?\]+<&$C_ODBO,=>_9#TFX5FTC6+FS;LMRHE
M7],&OH,/Q-A9KEK)IGR&*X+S"CK1M-'RMN(! /'I1D^O/K7KWB#]EWQIHZE[
M6&UU:/TM9P'_ /'PHKS;6/"NL>'7VZEI=U9'_IM"R#\S@5]!1S#"8C^'43/E
M,1E6-P7\:DXG,:KX9TG7 ?M^FV]R3U9XQN_/K7&:M\"] O'W6;W6G2>BMO7_
M +Y;)_6O1^1UR,?>S@8_4TF!TQQZ=J[^6*W,J./Q.&=J=1G@>K? ?6[-6>RN
M+>_B]3F(_KD?K7%:MX4UC0=W]H:;<6RC^)D)'_?0ROZU]7_Q$CAO[PZ_G1@8
M(QQZ=JR]G'J?0T.*,12TK)2/CI65NA&?KC].M%?4NL?#WP[KRL;K2X=[=)85
M,;#\5Q7"ZS\ ;2;<^DZI)">T=TH=?S7!J'2:/I\-Q'A:RY:FC/%**['6OA+X
MFT;)^P_;D_O6;>9_X[PWZ5R4D,MM(4GB>%QU5U(/]*SLSZ"EC*%;^'-,CHHP
M<9'2BD=MGV"BBBBPEKL%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH#<**** "BC@'YOE_P!Y@*U]%\)ZQXC91INGSW0_YZ!"
M(_\ OHX7_P >II7,*E:G15ZDK&12M\O4;?\ >&/ZUZMH7P#O;C:VJZA';?\
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ME&BE!X!X(/1LY%)2:L>@KM7044446%>^P4444AA1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>6APG^^3POXD5TSJ0HQYIM)'X-&G5Q4_<3E+MN8P^7IP?I3XH7FD"1QM(S'
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M5%Q<E+1'>45Y?XL^/.C>#]$\/ZI=V>I30:Y#Y]N((48QKM1OG^?C[Z_=W5S
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MA\WEL?+A!]E')_$U[/I>CV6BV:6UC:0V=O']R*$!5'T &*T5B55"J-J@8 '
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M.BF4@LX]\,/RJ7P#_P G6ZC_ -?U]_Z#)3OVC-+O?!WQ6TKQA;IO@D\B4/\
MPK+$P!4GI@J%ZXZU<6HXJ'=T_P 3+E?U::Z*?X'O!^#O@Y=%_LU?#VGBWV;/
M]0-_UW_>S[YS[UX!\"))_!GQSU+P['(\EI(US:ON. QB)*N??"_^/5ZRO[3'
M@K^Q_MGVZ;[0%_X\?L[^;O\ [O3;GWW8KRS]GS3[_P :?%;5O&$T1AM8VFF+
M ?*9I21Y:^HP6_(5Y]&%>%"L\1=1\^YW5I495Z+PV[[$VN*O_#7D? _X^;<Y
M[_\ 'JO^ KV;X]1K_P *G\1D@$^0!S_OK7AOQ8NI? ?[1EMXAO8I/L$KV]PC
MQINWQK&L<F/<;7..M=C\9/CAX5\0?#S4=-TO4#J-W?HJ1QQPNNSD-R2!Z8K6
MI3G7GA9P5TDOP[BA6C2A7C4=G=V+W[(__).=5/?^U9">?^F,->&_!SQSH7@7
M5K^XU_39-2MIH0D:1PQR[6W8_C([5]!?LP:#>:)\,7FNHFA_M"[>ZC1A@A"B
M(,_BA/XUX=^S_P")/#7AW7M3G\3O;BTDM]D7VBW:;Y]^<<*W:NJCK/%V7-Z'
M+54E'#)OE]3Z1^$OCOPWXYM;^X\/:1)IBP.D<PDMHXBY[?<)SC)_.O0V]>:X
M[P#XK\)>)!?#PL]N5M]IN%M[8P@%L[<Y5<_=-7OB!XL3P;X.U;6&/-M;L\8_
MO2$8C7\6*C\:^6G#FK<L8M-]SZ>G)1H\TM4?/6L>5\7/VD6LFW3Z7I8:)U&,
M8C4[LX/W3(3SUK1_9OU"7P?X\\2^"[M]I5W=,GCS$."!P,Y4ENG1:X/X5?#'
MQAXRL[W6]"UW^R")VMWE%S+"\I^5FR4!X^84>(-$U_X*_$S0M7UV_.IW4C_:
M6NUDD=I$#;'0LRD[BI_(U]=.-.4982,OLI6ZW1\E3E.,UBI1=^:_E8Z_]L!1
M_;_A[C&;:7/_ 'TO^-?4,8"PX_V:^:?VN-+FO(_#NMV_[ZQ"O$\B_=7=M9"3
MV#<\GTKN;#]I;P@WA>.ZN+^3^T! /,L?L[^9Y@7)7IMS[[L5Y-:E.MA*"IJ]
MKW/6I5H4L36=33L>8_LJY_X63K@SA?L<G';_ %L=:O[1O@^;PAXCT[Q]HN+:
M<3*+E1@ 2#[LN.^1G(_Q-5_V2=(NKCQ!KVNF+;9&#R$;LSLP8@'H0-G4>M0?
M%#7+OXU?%"Q\(:1(?[+M)B)9D(92Z_ZV0^R@;1_M9]17=)O^T)2O[L5KZ'#9
M?48QM[TGH1?#W3[S]H#XJ3^(=8C TC3U3_1RV5_V(P/0\L?HPKZLCCVC & !
M@5\EE[S]FWXL* 97\-7P4G)SNA)_]"1L_@?]JOJRPU!-0M8KF"59(9E#I(O(
M8$94CV(KRLR7-*,J?\/H>IEG+%.,_P")U/ /VPU T;PW_P!?$QZ_["UD?L[W
MQ\)_$_5?#LQ9(M1MUN(%]<*)%YZ_<D/Y5K_MB8_L;PV/^F\W_H*USGQ3C?P+
MKOP\\9VJG#64"S!?XBBKD'ZH^/\ @->MAY>TP,,,_M<UO5,\S$?N\9.NOLVN
M4_CE=/XZ^)^MPQ-NLO#VFR!F7L^P[B?3YY%7_@-=Y^S>H_X4QK;]_M%P<_2)
M/\*XGP%HLMW\'_B)XLOCYEYJBRH'8'.T?,S>^6<_]\5V_P"SA_R1+6SC_EXN
MO_124L3)1PRI+[$DO\Q4(\V)]K+JFSQ7X.>//#_@6^U"7Q!ILFIQW$02)8X4
MEP0W)^<CK7U'\*?''ASQUI=_=^'M*;38H9!'*)((XBS8_P!@G-?.7[/GB3PQ
MX;U35Y?$[6ZP2PQB'[1;F;D-SC"MBOI_P/XH\*>)K6\'A=[=DA*^>+>W,(#'
M.,Y5<]#66;+]XWR->?0URS2'Q*_8^=?V5M'LM;\4:U#?6L-W$MFI"S1AQG>!
MW'H:T?VF/ .G>$+G2-;T2!=-:XE,4D5N-D8=5+*X4< X!&0!TKG/V;_&VC^!
M_$6JW>M7@LX)K411L4=\MOSCY0>PK0^.'Q$B^,&N:1H7AF.6^CBD<!MA7S9&
M&!M'< +]XX'-=DXUEF'/*ZI]^AQP]E]2Y4OWGXG;?&C7'\2_L\Z)J<S'S[MK
M5Y#W\S:=WZ@UV_[..%^#F@GEN;@YQ\W_ !\25R'QU\/CPK\!=*TI"'^R26\+
ML#G+!6W'\3G\Z3P;XL'@W]EF'40Y6X6*YBMR.OF-<RA,>N.#^%>;4BJF#C"G
MUJ?@>E";I8MSJ=(7^9QEK80_&KX]:ZTI672[6&:%7V\!53RT(R1_$V[WQ72_
MLKZ]/INH>(_"-]N2YMIC.JL,,'#&.4<\\$+^=<#\)_A)XQ\2>'Y-:\.Z_P#V
M)#+(8OW=S-$T@7'/[L>Y'X4RWL]9^"?QBT6[UN\%_)+B:XO(V9]\4F8W8EN2
M<EC^ ->G6A"M&IA823M%)+K='ETJE2E*G7E%ZR;OY,V_VA=+N=!^+5GK^HV)
MU+17\AA&PS$P3AHF)X4G!//'->I^ ]6^&7Q$O;*YTS3=/MM:LV\Y(6@6WN$/
M]X ??'YU=\4?&+P79^(-3\+^) T9M]FYKBT,T$N] ^!M!YPX'([5\]>(/["C
M^+&B'X=23^7)-&Z1Q!@!,6^8(K@$)LP>>.6]*XZ<)8JA&$XN+BM)=/F=]1PP
MU9SA:2ENGN?;B_=%+34^Z*6OECZGH>*?$O\ :5L/ >O2:1::>VLW<.!/Y=PL
M:1D]B<,=WMBNB^$_QGLOBI'<1PVTFGWULH>6VD8/\I) *N.",CT[UX_\9OV?
M?$NK>,+W5]!@75+6^;SGA,R1O')_P-@"OZUV7[/'P9U7X?7=]J^M-%%>7$(@
M2VA.XHA()+-W.0.G2OH:E' QP7M(2_>'SE*MC7C.2:]P]S^\:\_^/2C_ (5/
MXBR,_N!UY_C6O0?3%>??'K/_  J7Q#_UP'_H:UXV&E:O3[71[6)_@R]#Y5^'
MUV? _B#P7XFQY=G-<203/U&T-MD)SW"2C\LU[7^U'JCZFGAOPE9E);K4[OS&
M5N2 /DC!'H6<_P#?%>;VWAD:S^S7)?*N;C3=2:<'G(0[(W_HWX5L_!VXNOBM
M\6K+6;X%X=$TZ-3NY_>*FS&?]\N__ :^NKN%2K];ZT[_ / /D:-Z=)X6VDR;
M]F2QBL?BQXFM4 \N&WFC3(["=<#]!6#\6-5M-#_:.O=0O[=KJRMY[9IH4B\S
M*_9X^Q.#73_LZX_X7)XO]=EQ_P"E"USWQ(O-/L?VFI[O5?+_ +-BNK5YVG4/
M'L%O'DE:49.6/JR:^Q?\AR4?J4(W^W8]9^&OQ<\%>,O%5OI^D>'I-/U)XY)$
MGEM8(RH48/S(Q(R.*\S^(D,=U^U)8PNBO$]Y9*R, 5(*QY!%>T^$OB!\/=9\
M0067A^>Q?4YPXC6WM3&Q 4L?FV^@->'_ !2U*VT7]I>"_NY?)MK6YLY99&&0
MJ*D9)P.>E>=@XR^L34(M/E>CW.[$N/U>/,TTI:GJ_P <OA5H.I> ]5U"TTVV
ML]1T^)KM+BWC$;,$&Y@< ;LJ#US7/?LX^)+C4OA=KVGW#-(NG[_*9CG]VT9(
M7\"I_.H_C%^T!H-]X,O=)T*Z:_NM0C,'F"-TC1&.&)+ $D@G@5I? ?P9>>%_
MA9K%S>Q-;W.I++,(Y!]V/R]L?'OR?QK->TAA.6OO>ZN5[E3%\U#:UM#C_P!D
M!1_;_B XSBVBQ_WTW^ KD+CQ%I7A7X]Z]J>M69OK"&^N@UND*2%MQ<='8#C)
M-=A^Q^P&O^(<G_EVB_\ 0FKG;75M%T;]H[6[O77ACTI+^[#FYC\Q.0X'R_4B
MO6:3Q=>ZO[AYVJPU*S^U8]N^%7Q.\(^.M<N;30="ETV]@@\YY)+2*([-RK@%
M"?[V?PKP/Q1X4?QI\:/%VE6P(N7DN)+=<\,ZC<5^A"D?C7TGX,\>> ]:UAK/
MPW+9?;VC+%+>S,3%1U&2J\5Y!X'56_:KU@ #;YMUSC_9KSL#4GAZE6I%.+4>
MIZ&+@JM.E3;3][H='^S%\2#JFB3^%=0D9;_303;^9D,\((!'U0G!_P![V-8W
M['(_>>+B>F+/_P!K5F?&K0+KX2_$NP\9:-&5M+N;S&C4X7S<$21GT#AB?KNK
M5_8[(:;Q@J_=S:@9_P"VU:U8Q^J5J\-I\OYZF%.<OK=*A/>%_P CR3Q9H[ZO
MXX^(<B#,ME<75Z& .[:+ORR,^@$N[_@-?2&G_$P1_L]?\)(TI-Y'8-;%LC<;
MD'R?S+\_2O-OA;I<6N?';XBV%PI,%U'J4#CV:Z0'^9KS:&\U=K!OAP WF/K0
M!';S0/*(^F[G]:ZJD%C(QIR=E3Y7\NIC3J/#.4XKXKKYD%CH,NC:MX+N9<K)
MJ$T=USP0OVAD7\. WXU[?^V$@71?#6.\\QZ_[*US?QPTJ+0_B=X$TZW!^SVU
MM:P(#Z+,0/TKI/VPCG0_#7_7>;_T%:7MO;XC#U'UN*--4</7AVL>H^!?#NDZ
M[\-_" U#3+2^,.EVOE_:8%DV?N4Z9''05X)I.A:;)^U5)IS:?:M8"XG46I@7
MR\"V)^[C'45]&?"_!^&_A7(_YA=K_P"B5KP'1?\ D[R7U^TW'_I*U>;@96>(
M3?V96]3U<5%2A1=MVCZ''@/PTL9C&@:;L)W%/LD>-WKT]Z^9_'NAZ=9_M*:/
MI\%A:Q6)N;,&WCA58SG&<J!CO7UICJ!QQ7RQ\1/^3I-%_P"OJQ_FM8994G*=
M2[^PRLPIP4(6BM9'OFO>%]'T;PMKDEAI=G8.;"8%K>!8SC83C('J*^4/@QX^
M\.> _P"V#XATJ;5?M7D^1Y=M'+M*>9O'SL,??6OL'QKQX0UKM_H4W_HMJ^5/
MV=_$WA'PW)KS>*6M LPM_LPN+0RYQYN[HK8SE?RK;!<T\-5;3;TT1SXZ,8XB
MG%67FSWKP5XPT'QMX'US4O#NE-IT$8E@=7ACB)<0A@<(3GAU_,UY-^Q^B_V]
MXAX_Y=HL?]],/Z5[3H_BOPMXB\*ZU_PC$L+0112>:MO 80&*'!P57G"C\J\7
M_8_Q_;_B'M_HT7_H355'3"XA--;>I=36O0LT][V*GA=%'[6LHVC_ (_KSM_T
M[R5]8CMZ=Z^/8?$-CX7_ &GKW5-2N5L[*"^NB\S@L.874<#GJ17T-I7QN\&:
MWJ=OIUCKD5Q=W#>7%$L,@)8]!DKBL\RHU).E)1=N5%Y?6IP51.6O,SQ/157_
M (:]E&!_Q]7!S_VZO_B:]B_:"Q_PJ'Q!V(2+G_MLE>'>.KR;X7_M'+K]]'(U
MC++]I$BIG=&\11]OJ1\W YXKK?C9\</"WB/X=WVDZ1?MJ%[>^6JHL3)M <.2
M2X4=%Q714HSK5L/4@KQM&_RW.:G6C1IUZ<])-NWS+G[..5^"^M,.#]IN#^42
M?X5\^:'X2N=3\&:MKMB6$^C7$+2;20VQP1N&.X9>O^T?05]*? ?0;S0_@K=_
M;$,#7?VBY6-Q@JA4*,_]\$_C7*?LDV4.I:5XJM+I/.MYFA21&/W@4<$5TPQ*
MH/$58O:2^Z^ISU*'M51I-;K[F:>N?$)?B)^S9JMXY']I0)#!=A<9#B6/!^C#
M!_/TIWPMUZ;PM^S3J.J6Y;[1 +GRVXRKERH;\R#7CWC?2;_X1^(/$?AHB0Z5
MJD.(LGATW[HG^H9=K>GS5['\(_#[^+/V<[[1XR?-NA=(G/\ 'DE1^8%*O1IT
MJ"E'X)3O\BJ%:=7$-2^*,;?,X[]GOP+H>N:9KOBOQ-&M[;6<C!DN3YD898Q(
M\C+_ !D @<Y[UZ)9?$/X+_VK87%H;)+ZWDW6SPZ9/&0S< \1#/X].M>8_!'X
MBZ9X&M=;\*>+(YK&SNI65M\;C8Y4(Z, -PRH'(XKG?B.W@YO'6B#P2$;3L1^
M:(?,/[WS&[OSTVU53#RQ&(E[1R4>EOA^\5.O&A0BXJ+EUON?<([8Z4M-C^XO
MTIU?'GV"V"BBB@84444 %%%% #>U-VCCM3Z-HI;@1[5V\# ]!6-X@\':+XHM
M3#JNGPWL?;S4R5_W3U'X5N[12;!C%7&4H/FB[,RJ4H5H\M171\W^-/V1[*ZD
M,_AW4&L2<9M;L&2/_@+9W#\2:*^D/+'I17NT\]QU./*IW]3Y6MPKEE:?.X6]
M!U%%%> ?7A1110 4444 %%%% !1110 4444 ,]ZY6V^&'ANS\8/XHBT_;K;E
MF-SY\AY*[3\N[;T)'2NLVCTHVBG&4HWL]R)04[<RV.,U3X2^%-:\4)XAO-*6
M;6$D25;@S2#YDQM)4-M.-HZCM5GQG\-?#OQ ^Q#7M/\ MWV/?Y/[^2/;OV[O
MN,,YVKU]*ZG8.*7:*OVE2Z?-L1[&G9KEW.>\7>!M%\>:;%8:Y9_;;6.43)&)
M7CPX!4'*$'HQ_.N0_P"&;OA[WT%B/3[;<8Z ?\]/85Z?M%+M%5&O6IJT)-+U
M)EAZ-1\TXILY;6/AQX=U[PW9^'[ZP,VE68C$$'GR*4V+M3Y@P8X'')Y[USD7
M[.?P_AD61= !=>A>[G;]"YKTS:/2C:/2B->M%6C-KYBEAZ4W>449FEZ%8:+;
M);:?9PV<$?W8H$"*/? [U@>(/A-X8\4^((=;U33/M&J1;-DWVB5,;#E?E5@.
M#[5V6T4;1Z5"J3B^92U[FCI4W'EY=#C;_P"$?A75/%,?B.YTPR:PDB2K<-<2
MX#)C:=N[;Q@<8Q77>6*DVBEI2DY6YG>PXPC&[BK7.+\/_";PKX9\02ZWIFEF
MVU.4N7F6XE(.\Y;Y2Q7'MCZ5UUU:QWEO)!*-T4BE&7)&01@BI<#THVBB4YR?
M,W=C5.$5RQ5D<EX,^%_AKP#<7$VA:=]CFN%V2-Y\DFY02<?.Q[GM4'B;X1>%
M/%^KQZIJVDK/?QJJ+/'-)$P"G*_<8<@]^M=IM'7%&*KVE3FYN;5D^RI\JC;1
M'%^+/A!X3\<:A%>ZUIAO+J.%8%D-S,F$#%@,*X'5FYZ\UF:;^SYX"TG4+:^M
M-"\NZMI4FB<W<[!74@J<%\<$#M7HVT>E+M%5[:JH\BF[>I#P]*3YG%7.,\7?
M"7PKX\OH;S7-,^VW,,8A1Q<2IA02<81@.I-8?_#.'P]Q_P B^3_V^W'_ ,<K
MT_:*-H]*<<16C%1C-I+S$\-1D^9P3.+\3?"+PGXSDM9-7TO[4]K"((2+B5-J
M Y ^5AGZGFL>#]G3P!;31S1Z"5DC975OMMQP1T_Y:5Z9M%&T>E"Q%>*Y8S:7
MJ#PU&3NX*YQD?PE\*Q^*_P#A)/[,W:SYGF_:GN)6^;&,[2VWZ#&!VKK?+SNS
M4V*-HK&4I2MS.]C:,(P345:YPNC_  5\&^'YKN6RT2-3=QF&=)II)8W0D'!1
MV*]0.W:L_P#X9Y^'[2^8-!4?[*W,RI]-H?&/;%>E;1Z4;16RQ%9-OG=_4P^J
MT/Y$9-CX;TS2])_LRTLHK:PV&/R(5V+M(P>GM7!_\,V_#MNN@D^QO+@]\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
